{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
vitamin a palmitate
to a specific field?
Status:
Investigational
Source:
NCT00842335: Phase 1/Phase 2 Interventional Completed Advanced Solid Tumors
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
CGI-1842 (also known as JI-101) is an oral multi-kinase inhibitor that targets vascular endothelial growth factor receptor type 2 (VEGFR-2), platelet derived growth factor receptor β (PDGFR-β), and ephrin type-B receptor 4 that has been used in trials studying the treatment of Cancer, Colon Cancer, Neuroendocrine, Ovarian Cancer, and Advanced Solid Tumors. By targeting multiple angiogenesis signaling pathways in tumor vessel beds, CGI-1842 has the potential to inhibit multiple stages of tumor angiogenesis and thus enhance anti-tumor efficacy. In preclinical models, CGI-1842 induced concentration-dependent blocking of both EphB4- and VEGF-stimulated signaling pathways and has shown excellent antitumor activity. CGI-1842 is well tolerated in cancer patients and has shown impressive activity in Phase I clinical trials.
Status:
Investigational
Source:
NCT00344812: Phase 2 Interventional Completed Opioid Dependence
(1996)
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
Dimepheptanol is one of the phenylpiperidine series, an opioid receptor agonist, which is active as an opioid analgesic. It is also elaborated in a number of close analogues, derivatives or diastereoisomers with similar properties. Dimepheptanol is a synthetic narcotic analgesic that has no accepted medical use in the United States.
Status:
Investigational
Source:
NCT00937937: Phase 2 Interventional Active, not recruiting Acral Lentiginous Melanoma
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Dinaciclib (SCH 727965) is a small molecule inhibitor of cyclin-dependent kinases. Dinaciclib demostrates potent and selective inhibition of CDK2, CDK5, CDK1, and CDK9 activity. Dinaciclib inhibits cell cycle progression and proliferation in various tumor cell lines in vitro. Dinaciclib is a product of a drug discovery collaboration between Pharmacopeia (later Ligand Pharmaceuticals) and Schering-Plough (later Merck & Co.) that began in 1998. Dinaciclib showed promising effect in treating haematological malignancies and solid tumors.
Class (Stereo):
CHEMICAL (ACHIRAL)
Guanoctine was studied as an antihypertensive agent.
Class (Stereo):
CHEMICAL (MIXED)
Rioprostil is a methylprostaglandin E1 analog. Rioprostil inhibits gastric acid secretion and enhances the gastric mucus-bicarbonate barrier. In peptic ulcer cases, it facilitates the healing process and the elimination of pain. Rioprostil can also be used to prevent recurrence of duodenal ulcers. However, its development has been discontinued in 2000.
Status:
Investigational
Source:
NCT02286518: Phase 1 Interventional Completed Clinical Pharmacology
(2014)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Meisoindigo ((E)-1,1'-dimethyl-[3,3'-biindolinylidene]-2,2'-dione) is a derivative of Indigo Naturalis, that has been used in China for chronic myeloid leukemia. In vitro cell line studies have shown that this agent might induce apoptosis and myeloid differentiation of acute myeloid leukemia (AML). Meisoindigo has been a routine therapeutic agent in the clinical treatment of chronic myelogenous leukemia (CML) in China since the 1980s. In phase III clinical trial of Meisoindigo involving 402 patients, it was shown that Meisoindigo was equally efficient for both newly diagnosed and previously treated CML patients after oral administration. The hematological complete response (CR) and partial response (PR) rates, respectively, were 45.0 and 39.3% for newly diagnosed patients and 35.9 and 41.4% for previously treated patients. Meisoindigo was generally well tolerated. The most frequent
side‑effects were bone, joint and/or muscle pain of varying degrees when the dosage was more than the suitable one.
Status:
Investigational
Source:
NCT01924858: Phase 1 Interventional Terminated Alzheimer's Disease
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT03692312: Phase 2/Phase 3 Interventional Completed Congenital Myotonic Dystrophy
(2021)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Tideglusib (NP031112, NP-12, Nypta, Noscira SA, Madrid, Spain), a drug, which belongs to the thiadiazolidinone family, is a GSK-3β inhibitor. Tideglusib was in phase II clinical trials for the treatment of Alzheimer disease (AD) and progressive supranuclear palsy. Participants showed no benefit on either of the primary outcome measures or exploratory endpoints and further development in the drug was halted for these two disease. However, Tideglusib is on phase II clinical trial to determine whether drug is safe and efficacious in the treatment of adolescents and adults with congenital and juvenile-onset Myotonic Dystrophy.
Class (Stereo):
CHEMICAL (RACEMIC)
Proflazepam is benzodiazepine derivative patented by Hoffmann-La Roche, F., und Co., A.-G. as anticonvulsant and muscle relaxant. In preclinical studies, Proflazepam shows activity in pentetrazole test and in the rotating rod test.
Class (Stereo):
CHEMICAL (RACEMIC)
Brolaconazole is imidazole derivative with potent antimicrobial activity against pathogenic fungi, molds, yeasts, and Gram-positive bacteria. Brolaconazole showed an inhibition band of 20-40 mM against Candida albican and it demonstrates higher activity compare bifonazole. Brolaconazole is useful for the treatment of dermal and vaginal infections such as vaginal candidiasis, tinea corporis, tinea pedis, tinea cruris, and other dermal infections.
